Masaaki Okihara

Mx. Masaaki Okihara

東京医科大学八王子医療センター腎臓移植科

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MOMasaaki Okihara
Masaaki Okihara
HTHironori Takeuchi
Hironori Takeuchi
YKYukiko Kikuchi
Yukiko Kikuchi
IAIsao Akashi
Isao Akashi
YKYu Kihara
Yu Kihara
俊平俊 彦 平野
俊 彦 平野
Recently, steroid reduction/withdrawal regimens have been attempted to minimize the side effects of steroids in renal transplantation. However, some recipients have experienced an increase/resumption of steroid administrations and acute graft rejection (AR). Therefore, we investigated the relationship between the individual lymphocyte sensitivity to steroids and the clinical outcome after steroid reduction/withdrawal. We cultured peripheral blood mononuclear cells (PBMCs) isolated from 24 recipients with concanavalin A (Con A) in the presence of methylprednisolone (MPSL) or cortisol (COR) for four days, and the 50% of PBMC proliferation (IC50) values and the PBMC sensitivity to steroids were calculated. Regarding the experience of steroid increase/resumption and incidence of AR within one year of steroid reduction/withdrawal, the IC50 values of these drugs before transplantation in the clinical event group were significantly higher than those in the event-free group. The cumulative incidence of steroid increase/resumption and AR in the PBMC high-sensitivity groups to these drugs before transplantation were significantly lower than those in the low-sensitivity groups. These observations suggested that an individual’s lymphocyte sensitivity to steroids could be a reliable biomarker to predict the clinical outcome after steroid reduction/withdrawal and to select the patients whose dose of steroids can be decreased and/or withdrawn after transplantation.

21 September 2026 in Renal Replacement Therapy
Verified
Journal Article
Open access
PDF file
MOMasaaki Okihara
Masaaki Okihara
TOTakashi Oda
Takashi Oda
SYSakiko Yamaguchi
Sakiko Yamaguchi
TUTakahiro Uchida
Takahiro Uchida
MKMakoto Kimura
Makoto Kimura
HIHitoshi Iwamoto
Hitoshi Iwamoto
Background: Antibody-mediated rejection (AMR) can occasionally present with hemorrhagic necrosis and histopathological findings resembling adenovirus nephropathy (ADVN), making differentiation between these conditions challenging. In addition, coexistence of rejection and adenovirus (ADV) infection has been reported, further complicating the diagnosis. Herein, we report a case of AMR with hemorrhagic necrosis requiring differentiation from ADVN. Case presentation: A 71-year-old man on chronic hemodialysis for end-stage renal disease due to benign prostatic hyperplasia underwent an ABO-incompatible living-donor kidney transplant from his wife. Post-transplant, he showed no evidence of de novo donor-specific antibodies or rejection on protocol biopsies. Twenty-two months after transplantation, he presented with gross hematuria, graft swelling, and a rapid rise in serum creatinine (1.4 → 7.9 mg/dL). Steroid pulse therapy was initiated after an allograft biopsy for suspected rejection. Pathological findings made it difficult to distinguish between AMR and ADVN. As anti-human leukocyte antigen antibodies turned positive, the patient was treated for AMR with rituximab, double filtration plasmapheresis, and intravenous immunoglobulin. Although gross hematuria resolved, graft function did not improve. ADV was not detected by polymerase chain reaction (PCR) testing of urine or blood, nor by virological examination of the biopsy specimen. A repeat biopsy 2 weeks later revealed AMR accompanied by hemorrhagic necrosis. Despite outpatient follow-up, graft function gradually declined, and dialysis was resumed. Conclusions: We encountered a case of AMR of renal allograft showing hemorrhagic necrosis mimicking ADVN. Because these conditions can coexist, comprehensive assessment—including clinical course and virological, pathological, and immunological findings—is essential for accurate diagnosis and appropriate management.